Citigroup’s Viking Therapeutics VKTX Stock Holding History

Citigroup’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,200	Closed	-$57K	–	7459
2020 Q4	$57K	Buy	10,200 +300	+3%	+$1.82K	﹤0.01%	5950
2020 Q3	$58K	Sell	9,900 -1,500	-13%	-$10.3K	﹤0.01%	5504
2020 Q2	$82K	Buy	11,400 +1,500	+15%	+$9.96K	﹤0.01%	5743
2020 Q1	$46K	Sell	9,900 -23,300	-70%	-$143K	﹤0.01%	6043
2019 Q4	$266K	Sell	33,200 -2,800	-8%	-$20.4K	﹤0.01%	4944
2019 Q3	$248K	Sell	36,000 -15,500	-30%	-$115K	﹤0.01%	4969
2019 Q2	$427K	Buy	51,500 +13,600	+36%	+$116K	﹤0.01%	4574
2019 Q1	$377K	Buy	37,900 +13,600	+56%	+$114K	﹤0.01%	4489
2018 Q4	$186K	Buy	24,300 +2,300	+10%	+$27.5K	﹤0.01%	5086
2018 Q3	$383K	Buy	+22,000	New	+$262K	﹤0.01%	4594

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Citigroup's VKTX Position: Q1 2026 in Review

Citigroup increased its Viking Therapeutics (VKTX) stake by 59% in Q1 2026, buying an estimated $1.31M and bringing the position to 109,295 shares worth $3.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2237.

Citigroup first reported a position in VKTX in Q1 2016 and has held it in 33 quarters since. The position peaked at $22.9M in Q2 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Citigroup held 109,295 shares of Viking Therapeutics worth $3.56M as of Q1 2026.
Citigroup bought 40,640 Viking Therapeutics shares in Q1 2026, an estimated $1.31M.
Viking Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2237 holding.
Citigroup first reported a position in Viking Therapeutics in Q1 2016 and has held it in 33 quarters since.
Citigroup's Viking Therapeutics position peaked at $22.9M in Q2 2025.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.